Even with well‑executed standard secondary prevention therapy, many patients who survive acute coronary syndrome continue to face elevated chances of recurrent heart‑related complications. A new review published in Cardiology Discovery lays out a structured clinical framework to identify and manage residual cardiovascular risks for these high‑risk survivors.
While modern care for acute coronary syndrome, including revascularization, statins, and antiplatelet therapies, has lowered short‑term mortality, a notable share of patients still experience major adverse cardiovascular events months or years after their index episode. Persistent residual risk stems not only from vulnerable non-culprit lesions, but also from incomplete control of blood lipids, unresolved inflammation, thrombotic activity, and sub‑optimal lifestyle factors that standard treatment pathways may overlook. Clinicians lack unified practical guidance covering all these overlapping risk sources in post-acute coronary syndrome care.
In this narrative review, researchers from Chinese medical institutions consolidated recent guideline recommendations and high‑quality clinical evidence focusing on patients recovering from acute coronary syndrome. The authors grouped residual cardiovascular risks into four practical categories: non-culprit lesion instability, lipid‑associated residual risk, inflammatory residual risk, thrombotic residual risk, and modifiable lifestyle‑driven risk. They summarized existing therapeutic options including implementation of precision revascularization strategies by intracoronary imaging and fractional flow reserve assessment, newer lipid‑lowering agents, anti‑inflammatory therapies, optimized anti‑thrombotic regimens, alongside lifestyle modification and cardiac‑rehabilitation strategies for each risk subgroup. Rather than proposing one‑size‑fits‑all treatment, the paper emphasizes repeated risk re‑evaluation to support personalized clinical decision‑making for individual patients.
“Many post-acute coronary syndrome patients achieve basic treatment targets yet remain at substantial event risk,” said corresponding author Dr Weifeng Shen. “Clinicians need systematic thinking to detect these hidden residual risks and select appropriate add‑on interventions beyond baseline secondary prevention measures.”
This work is a narrative evidence‑synthesizing review and carries inherent limitations. It does not produce original patient‑level trial data; clinical decision‑making still needs to balance individual patient comorbidities, bleeding risks and drug tolerability. Prospective real‑world studies are required to further verify the clinical benefits of this multi‑dimension risk management workflow. Moving forward, the framework may help design better follow‑up protocols for acute coronary syndrome survivors in routine clinical practice.
The article “Optimal Management of Residual Cardiovascular Risks After Acute Coronary Syndrome” is available online in Cardiology Discovery , DOI: 10.1097/CD9.0000000000000201.
Cardiology Discovery
Literature review
Not applicable
Optimal Management of Residual Cardiovascular Risks After Acute Coronary Syndrome
7-Jul-2026